MedTrace Logo

Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00544011 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2011-06-27

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well bevacizumab given together with combination chemotherapy works in treating patients with metastatic colorectal cancer.

Conditions

Interventions

BIOLOGICAL

bevacizumab

DRUG

capecitabine

DRUG

fluorouracil

DRUG

irinotecan hydrochloride

OTHER

diagnostic laboratory biomarker analysis

Sponsors & Collaborators

  • Hopital Jean Minjoz

    lead OTHER

Principal Investigators

  • Christophe Borg, PhD · Hopital Jean Minjoz

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544011 on ClinicalTrials.gov